GILD
Gilead Sciences, Inc.
Price Chart
Latest Quote
$125.87
+4.39 (+3.61%)
Current Price
| Previous Close | $121.48 |
| Open | $121.79 |
| Day High | $127.37 |
| Day Low | $121.79 |
| Volume | 8,500,387 |
Stock Information
| Quarterly Dividend / Yield | $3.28 / 2.61% |
| Shares Outstanding | 1.24B |
| Quarterly Dividend Yield | 2.61% |
| Quarterly Dividend | $3.28 |
| Total Debt | $22.17B |
| Cash Equivalents | $9.82B |
| Revenue | $29.74B |
| Net Income | $9.22B |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Market Cap | $155.93B |
| P/E Ratio | 17.09 |
| EPS (TTM) | $7.35 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $168.20B |
| Sales | $29.74B |
| Income | $9.22B |
| Book/sh | $18.93 |
| Cash/sh | $7.91 |
| Employees | 17K |
Financial Ratios
| Quick Ratio | 1.54 |
| Current Ratio | 1.97 |
| Debt/Eq | 94.64 |
| EPS Growth TTM | 53.70% |
Returns & Margins
| ROA | 13.29% |
| ROE | 43.36% |
| Gross Margin | 79.37% |
| Operating Margin | 39.28% |
| Profit Margin | 30.99% |
Ownership
| Insider Ownership | 0.12% |
| Institutional Ownership | 92.21% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 13.02 |
| PEG | 2.14 |
| P/S | 5.24 |
| P/B | 6.63 |
Analyst Data
| Recommendation | buy |
| Target Price | $157.57 |
Technical Indicators
| SMA20 | $129.80 |
| SMA50 | $132.97 |
| SMA200 | $128.33 |
| RSI | 33.02 |
| ATR | 3.6786 |
| Shares Float | 1.24B |
| Short Float | 2.07% |
| Short Ratio | 3.92 |
| Volatility | 0.33 |
| Rel Volume | 0.65 |
Performance History
| Week | -2.76% |
| Month | -5.61% |
| Quarter | -13.38% |
| 6 Months | +4.78% |
| YTD | +3.87% |
| Year | +17.96% |
| 3 Years | +82.75% |
| 5 Years | +124.43% |
| 10 Years | +112.90% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-12 | $125.59 | 5,214,600 |
| 2026-06-11 | $125.87 | 8,665,600 |
| 2026-06-10 | $121.48 | 10,154,200 |
| 2026-06-09 | $125.50 | 8,683,100 |
| 2026-06-08 | $128.10 | 9,796,000 |
| 2026-06-05 | $129.16 | 15,369,400 |
| 2026-06-04 | $129.18 | 13,729,200 |
| 2026-06-03 | $128.99 | 6,237,100 |
| 2026-06-02 | $127.57 | 8,082,600 |
| 2026-06-01 | $131.10 | 6,259,200 |
| 2026-05-29 | $134.43 | 17,509,800 |
| 2026-05-28 | $136.22 | 5,610,000 |
| 2026-05-27 | $133.69 | 5,032,000 |
| 2026-05-26 | $133.73 | 6,408,900 |
| 2026-05-22 | $134.36 | 5,973,400 |
| 2026-05-21 | $130.50 | 4,920,800 |
| 2026-05-20 | $130.69 | 5,571,000 |
| 2026-05-19 | $130.50 | 5,009,000 |
| 2026-05-18 | $129.67 | 5,182,200 |
| 2026-05-15 | $129.58 | 6,640,700 |
| 2026-05-14 | $132.06 | 4,533,200 |
| 2026-05-13 | $133.05 | 6,666,700 |
About Gilead Sciences, Inc.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
đ° Latest News
Is Gilead (GILD) One of the Top Large Cap Value Stocks to Buy Now?
Insider Monkey âĸ 2026-06-11T19:55:05Z
Gilead Sciences, Inc. (GILD): a Top Deep Value Stock Making Progress on Pipeline Development
Insider Monkey âĸ 2026-06-11T01:00:08Z
Can Gilead Sciences HIV Franchise Drive Long-Term Growth?
Zacks âĸ 2026-06-10T18:12:00Z
Cencora Kite Deal Highlights CAR T Growth And Undervalued Share Price Potential
Simply Wall St. âĸ 2026-06-10T14:05:45Z
Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC Study
Zacks âĸ 2026-06-09T19:31:00Z
Gileadâs Mixed Trial News Puts HIV Progress And Oncology Risks In Focus
Simply Wall St. âĸ 2026-06-09T17:09:59Z
Stocks Climb on an AI-Led Rebound
Barchart âĸ 2026-06-09T14:08:17Z
Merck, Gilead report mixed outcomes in key lung cancer, HIV studies
BioPharma Dive âĸ 2026-06-09T12:21:00Z
Will HIV Win and Lung Cancer Loss in Trials Recast Merckâs (MRK) Risk Reward Narrative?
Simply Wall St. âĸ 2026-06-09T08:08:04Z
Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead
MarketBeat âĸ 2026-06-08T17:03:15Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $6,234,000,000 | $6,251,000,000 | $6,498,000,000 | $5,657,000,000 |
| Cost Of Revenue | $6,234,000,000 | $6,251,000,000 | $6,498,000,000 | $5,657,000,000 |
| Total Revenue | $29,442,000,000 | $28,754,000,000 | $27,116,000,000 | $27,281,000,000 |
| Operating Revenue | $29,442,000,000 | $28,754,000,000 | $27,116,000,000 | $27,281,000,000 |
| Expenses | ||||
| Interest Expense | $1,024,000,000 | $977,000,000 | $944,000,000 | $935,000,000 |
| Total Expenses | $17,741,000,000 | $18,158,000,000 | $18,278,000,000 | $16,307,000,000 |
| Other Income Expense | $-1,230,000,000 | $-9,210,000,000 | $-1,411,000,000 | $-4,330,000,000 |
| Other Non Operating Income Expenses | $-1,000,000 | $-2,000,000 | $-11,000,000 | $-29,000,000 |
| Net Non Operating Interest Income Expense | $-675,000,000 | $-696,000,000 | $-568,000,000 | $-829,000,000 |
| Interest Expense Non Operating | $1,024,000,000 | $977,000,000 | $944,000,000 | $935,000,000 |
| Operating Expense | $11,507,000,000 | $11,907,000,000 | $11,780,000,000 | $10,650,000,000 |
| Selling And Marketing Expense | $3,522,000,000 | $3,453,000,000 | $3,272,000,000 | - |
| General And Administrative Expense | $2,186,000,000 | $2,547,000,000 | $2,790,000,000 | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $8,510,000,000 | $480,000,000 | $5,665,000,000 | $4,592,000,000 |
| Net Interest Income | $-675,000,000 | $-696,000,000 | $-568,000,000 | $-829,000,000 |
| Interest Income | $349,000,000 | $281,000,000 | $376,000,000 | $106,000,000 |
| Normalized Income | $9,577,659,249 | $6,872,220,290 | $6,810,200,000 | $7,969,771,930 |
| Net Income From Continuing And Discontinued Operation | $8,510,000,000 | $480,000,000 | $5,665,000,000 | $4,592,000,000 |
| Total Operating Income As Reported | $10,022,000,000 | $1,662,000,000 | $7,605,000,000 | $7,330,000,000 |
| Net Income Common Stockholders | $8,510,000,000 | $480,000,000 | $5,665,000,000 | $4,592,000,000 |
| Net Income | $8,510,000,000 | $480,000,000 | $5,665,000,000 | $4,592,000,000 |
| Net Income Including Noncontrolling Interests | $8,510,000,000 | $480,000,000 | $5,613,000,000 | $4,566,000,000 |
| Net Income Continuous Operations | $8,510,000,000 | $479,000,000 | $5,612,000,000 | $4,566,000,000 |
| Pretax Income | $9,796,000,000 | $690,000,000 | $6,859,000,000 | $5,814,000,000 |
| Special Income Charges | $-1,680,000,000 | $-8,934,000,000 | $-1,233,000,000 | $-3,644,000,000 |
| Interest Income Non Operating | $349,000,000 | $281,000,000 | $376,000,000 | $106,000,000 |
| Operating Income | $11,701,000,000 | $10,596,000,000 | $8,838,000,000 | $10,974,000,000 |
| Gross Profit | $23,208,000,000 | $22,503,000,000 | $20,618,000,000 | $21,624,000,000 |
| Per Share | ||||
| Diluted EPS | $6.78 | $0.38 | $4.50 | $3.64 |
| Basic EPS | $6.84 | $0.38 | $4.54 | $3.66 |
| Other | ||||
| Tax Effect Of Unusual Items | $-161,340,751 | $-2,815,779,710 | $-254,800,000 | $-923,228,070 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $14,809,000,000 | $13,642,000,000 | $11,896,000,000 | $13,153,000,000 |
| Total Unusual Items | $-1,229,000,000 | $-9,208,000,000 | $-1,400,000,000 | $-4,301,000,000 |
| Total Unusual Items Excluding Goodwill | $-1,229,000,000 | $-9,208,000,000 | $-1,400,000,000 | $-4,301,000,000 |
| Reconciled Depreciation | $2,760,000,000 | $2,767,000,000 | $2,693,000,000 | $2,103,000,000 |
| EBITDA (Bullshit earnings) | $13,580,000,000 | $4,434,000,000 | $10,496,000,000 | $8,852,000,000 |
| EBIT | $10,820,000,000 | $1,667,000,000 | $7,803,000,000 | $6,749,000,000 |
| Diluted Average Shares | $1,255,000,000 | $1,255,000,000 | $1,258,000,000 | $1,262,000,000 |
| Basic Average Shares | $1,244,000,000 | $1,247,000,000 | $1,248,000,000 | $1,255,000,000 |
| Diluted NI Availto Com Stockholders | $8,510,000,000 | $480,000,000 | $5,665,000,000 | $4,592,000,000 |
| Minority Interests | $0 | $0 | $52,000,000 | $26,000,000 |
| Tax Provision | $1,286,000,000 | $211,000,000 | $1,247,000,000 | $1,248,000,000 |
| Other Special Charges | $1,024,000,000 | $4,663,000,000 | $1,155,000,000 | $944,000,000 |
| Write Off | $590,000,000 | $4,180,000,000 | $50,000,000 | $2,700,000,000 |
| Restructuring And Mergern Acquisition | $66,000,000 | $91,000,000 | $28,000,000 | - |
| Gain On Sale Of Security | $451,000,000 | $-274,000,000 | $-167,000,000 | $-657,000,000 |
| Research And Development | $5,799,000,000 | $5,907,000,000 | $5,718,000,000 | $4,977,000,000 |
| Selling General And Administration | $5,708,000,000 | $6,000,000,000 | $6,062,000,000 | $5,673,000,000 |
| Other Gand A | $2,186,000,000 | $2,547,000,000 | $2,790,000,000 | - |
Fetched: 2026-05-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-2,590,000,000 | $-8,932,000,000 | $-11,935,000,000 | $-15,967,000,000 |
| Total Assets | $59,023,000,000 | $58,995,000,000 | $62,125,000,000 | $63,171,000,000 |
| Total Non Current Assets | $40,681,000,000 | $39,823,000,000 | $46,040,000,000 | $48,727,000,000 |
| Other Non Current Assets | $4,845,000,000 | $3,769,000,000 | $4,792,000,000 | $4,800,000,000 |
| Non Current Deferred Assets | $1,964,000,000 | $2,378,000,000 | - | - |
| Non Current Deferred Taxes Assets | $1,964,000,000 | $2,378,000,000 | - | - |
| Investmentin Financial Assets | $2,974,000,000 | $0 | $1,163,000,000 | $1,245,000,000 |
| Goodwill And Other Intangible Assets | $25,292,000,000 | $28,262,000,000 | $34,768,000,000 | $37,207,000,000 |
| Other Intangible Assets | $16,978,000,000 | $19,948,000,000 | $26,454,000,000 | $28,893,000,000 |
| Current Assets | $18,342,000,000 | $19,173,000,000 | $16,085,000,000 | $14,443,000,000 |
| Other Current Assets | $1,143,000,000 | $995,000,000 | $2,374,000,000 | $1,774,000,000 |
| Prepaid Assets | $899,000,000 | $480,000,000 | - | $1,774,000,000 |
| Inventory | $1,774,000,000 | $1,710,000,000 | $1,787,000,000 | $1,507,000,000 |
| Receivables | $4,913,000,000 | $4,420,000,000 | $4,660,000,000 | $4,777,000,000 |
| Accounts Receivable | $4,913,000,000 | $4,420,000,000 | $4,660,000,000 | $4,777,000,000 |
| Allowance For Doubtful Accounts Receivable | $-981,000,000 | $-900,000,000 | $-836,000,000 | $-687,000,000 |
| Gross Accounts Receivable | $5,895,000,000 | $5,319,000,000 | $5,495,000,000 | $5,464,000,000 |
| Cash Cash Equivalents And Short Term Investments | $9,613,000,000 | $11,568,000,000 | $7,264,000,000 | $6,385,000,000 |
| Cash And Cash Equivalents | $7,564,000,000 | $9,991,000,000 | $6,085,000,000 | $5,412,000,000 |
| Debt | ||||
| Net Debt | $17,372,000,000 | $16,720,000,000 | $18,902,000,000 | $19,818,000,000 |
| Total Debt | $24,936,000,000 | $26,711,000,000 | $24,987,000,000 | $25,230,000,000 |
| Long Term Debt And Capital Lease Obligation | $22,129,000,000 | $24,896,000,000 | $23,189,000,000 | $22,957,000,000 |
| Long Term Debt | $22,129,000,000 | $24,896,000,000 | $23,189,000,000 | $22,957,000,000 |
| Current Debt And Capital Lease Obligation | $2,807,000,000 | $1,815,000,000 | $1,798,000,000 | $2,273,000,000 |
| Current Debt | $2,807,000,000 | $1,815,000,000 | $1,798,000,000 | $2,273,000,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $36,405,000,000 | $39,749,000,000 | $39,376,000,000 | $41,962,000,000 |
| Total Non Current Liabilities Net Minority Interest | $24,592,000,000 | $27,745,000,000 | $28,096,000,000 | $30,724,000,000 |
| Other Non Current Liabilities | $1,165,000,000 | $1,295,000,000 | $1,280,000,000 | $1,178,000,000 |
| Tradeand Other Payables Non Current | $896,000,000 | $830,000,000 | $2,039,000,000 | $3,916,000,000 |
| Non Current Deferred Liabilities | $402,000,000 | $724,000,000 | $1,588,000,000 | $2,673,000,000 |
| Non Current Deferred Taxes Liabilities | $402,000,000 | $724,000,000 | $1,588,000,000 | $2,673,000,000 |
| Current Liabilities | $11,813,000,000 | $12,004,000,000 | $11,280,000,000 | $11,238,000,000 |
| Other Current Liabilities | $2,243,000,000 | $2,269,000,000 | $2,334,000,000 | $2,182,000,000 |
| Payables And Accrued Expenses | $5,144,000,000 | $6,371,000,000 | $5,560,000,000 | $5,343,000,000 |
| Payables | $807,000,000 | $2,479,000,000 | $1,758,000,000 | $1,864,000,000 |
| Total Tax Payable | $92,000,000 | $1,646,000,000 | $1,208,000,000 | $959,000,000 |
| Income Tax Payable | $92,000,000 | $1,646,000,000 | $1,208,000,000 | $959,000,000 |
| Accounts Payable | $715,000,000 | $833,000,000 | $550,000,000 | $905,000,000 |
| Equity | ||||
| Common Stock Equity | $22,702,000,000 | $19,330,000,000 | $22,833,000,000 | $21,240,000,000 |
| Total Equity Gross Minority Interest | $22,618,000,000 | $19,246,000,000 | $22,749,000,000 | $21,209,000,000 |
| Stockholders Equity | $22,702,000,000 | $19,330,000,000 | $22,833,000,000 | $21,240,000,000 |
| Gains Losses Not Affecting Retained Earnings | $39,000,000 | $132,000,000 | $28,000,000 | $2,000,000 |
| Other Equity Adjustments | $39,000,000 | $132,000,000 | $28,000,000 | $2,000,000 |
| Retained Earnings | $13,730,000,000 | $11,497,000,000 | $16,304,000,000 | $15,687,000,000 |
| Other | ||||
| Ordinary Shares Number | $1,240,679,623 | $1,246,265,857 | $1,246,041,895 | $1,247,000,000 |
| Share Issued | $1,240,679,623 | $1,246,265,857 | $1,246,041,895 | $1,247,000,000 |
| Tangible Book Value | $-2,590,000,000 | $-8,932,000,000 | $-11,935,000,000 | $-15,967,000,000 |
| Invested Capital | $47,638,000,000 | $46,041,000,000 | $47,820,000,000 | $46,470,000,000 |
| Working Capital | $6,529,000,000 | $7,169,000,000 | $4,805,000,000 | $3,205,000,000 |
| Total Capitalization | $44,831,000,000 | $44,226,000,000 | $46,022,000,000 | $44,197,000,000 |
| Minority Interest | $-84,000,000 | $-84,000,000 | $-84,000,000 | $-31,000,000 |
| Additional Paid In Capital | $8,932,000,000 | $7,700,000,000 | $6,500,000,000 | $5,550,000,000 |
| Capital Stock | $1,000,000 | $1,000,000 | $1,000,000 | $1,000,000 |
| Common Stock | $1,000,000 | $1,000,000 | $1,000,000 | $1,000,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $1,298,000,000 | $1,228,000,000 | $1,201,000,000 | $1,018,000,000 |
| Current Provisions | $321,000,000 | $321,000,000 | $387,000,000 | $422,000,000 |
| Current Accrued Expenses | $4,337,000,000 | $3,892,000,000 | $3,802,000,000 | $3,479,000,000 |
| Investments And Advances | $2,974,000,000 | $0 | $1,163,000,000 | $1,245,000,000 |
| Available For Sale Securities | $2,974,000,000 | - | $1,163,000,000 | $1,245,000,000 |
| Goodwill | $8,314,000,000 | $8,314,000,000 | $8,314,000,000 | $8,314,000,000 |
| Net PPE | $5,606,000,000 | $5,414,000,000 | $5,317,000,000 | $5,475,000,000 |
| Accumulated Depreciation | $-2,696,000,000 | $-2,470,000,000 | $-2,449,000,000 | $-2,186,000,000 |
| Gross PPE | $8,302,000,000 | $7,884,000,000 | $7,766,000,000 | $7,661,000,000 |
| Construction In Progress | $745,000,000 | $501,000,000 | $661,000,000 | $719,000,000 |
| Other Properties | $1,707,000,000 | $1,589,000,000 | $1,147,000,000 | $1,110,000,000 |
| Machinery Furniture Equipment | $666,000,000 | $692,000,000 | $1,069,000,000 | $880,000,000 |
| Buildings And Improvements | $4,622,000,000 | $4,539,000,000 | $4,328,000,000 | $4,390,000,000 |
| Land And Improvements | $561,000,000 | $561,000,000 | $561,000,000 | $562,000,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $2,049,000,000 | $1,577,000,000 | $1,179,000,000 | $973,000,000 |
| Treasury Shares Number | - | - | $0 | - |
Fetched: 2026-05-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $9,456,000,000 | $10,305,000,000 | $7,421,000,000 | $8,344,000,000 |
| Operating Activities | ||||
| Operating Cash Flow | $10,019,000,000 | $10,828,000,000 | $8,006,000,000 | $9,072,000,000 |
| Cash Flow From Continuing Operating Activities | $10,019,000,000 | $10,828,000,000 | $8,005,000,000 | $9,072,000,000 |
| Operating Gains Losses | $-451,000,000 | $274,000,000 | $167,000,000 | $657,000,000 |
| Investing Activities | ||||
| Capital Expenditure | $-563,000,000 | $-523,000,000 | $-585,000,000 | $-728,000,000 |
| Investing Cash Flow | $-4,793,000,000 | $-3,449,000,000 | $-2,265,000,000 | $-2,466,000,000 |
| Cash Flow From Continuing Investing Activities | $-4,794,000,000 | $-3,449,000,000 | $-2,266,000,000 | $-2,466,000,000 |
| Net Other Investing Changes | $3,000,000 | $58,000,000 | - | $-1,000,000 |
| Capital Expenditure Reported | - | $-523,000,000 | $-585,000,000 | $-728,000,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-1,922,000,000 | $-1,150,000,000 | $-1,000,000,000 | $-1,396,000,000 |
| Issuance Of Capital Stock | $408,000,000 | $422,000,000 | $232,000,000 | $309,000,000 |
| Financing Cash Flow | $-7,745,000,000 | $-3,433,000,000 | $-5,125,000,000 | $-6,469,000,000 |
| Cash Flow From Continuing Financing Activities | $-7,745,000,000 | $-3,433,000,000 | $-5,126,000,000 | $-6,469,000,000 |
| Net Other Financing Charges | $-440,000,000 | $-281,000,000 | $-278,000,000 | $-173,000,000 |
| Cash Dividends Paid | $-4,003,000,000 | $-3,918,000,000 | $-3,809,000,000 | $-3,709,000,000 |
| Common Stock Dividend Paid | $-4,003,000,000 | $-3,918,000,000 | $-3,809,000,000 | $-3,709,000,000 |
| Net Common Stock Issuance | $-1,514,000,000 | $-728,000,000 | $-768,000,000 | $-1,087,000,000 |
| Common Stock Issuance | $408,000,000 | $422,000,000 | $232,000,000 | $309,000,000 |
| Other | ||||
| Repayment Of Debt | $-1,788,000,000 | $-1,970,000,000 | $-2,250,000,000 | $-1,500,000,000 |
| Issuance Of Debt | $0 | $3,464,000,000 | $1,980,000,000 | $0 |
| Interest Paid Supplemental Data | $1,036,000,000 | $951,000,000 | $891,000,000 | $907,000,000 |
| Income Tax Paid Supplemental Data | $3,215,000,000 | $2,779,000,000 | $3,990,000,000 | $3,136,000,000 |
| End Cash Position | $7,564,000,000 | $9,991,000,000 | $6,085,000,000 | $5,412,000,000 |
| Beginning Cash Position | $9,991,000,000 | $6,085,000,000 | $5,412,000,000 | $5,338,000,000 |
| Effect Of Exchange Rate Changes | $92,000,000 | $-40,000,000 | $57,000,000 | $-63,000,000 |
| Changes In Cash | $-2,519,000,000 | $3,946,000,000 | $616,000,000 | $137,000,000 |
| Common Stock Payments | $-1,922,000,000 | $-1,150,000,000 | $-1,000,000,000 | $-1,396,000,000 |
| Net Issuance Payments Of Debt | $-1,788,000,000 | $1,494,000,000 | $-270,000,000 | $-1,500,000,000 |
| Net Long Term Debt Issuance | $-1,788,000,000 | $1,494,000,000 | $-270,000,000 | $-1,500,000,000 |
| Long Term Debt Payments | $-1,788,000,000 | $-1,970,000,000 | $-2,250,000,000 | $-1,500,000,000 |
| Long Term Debt Issuance | $0 | $3,464,000,000 | $1,980,000,000 | $0 |
| Net Investment Purchase And Sale | $-3,163,000,000 | $1,856,000,000 | $-528,000,000 | $60,000,000 |
| Sale Of Investment | $909,000,000 | $2,592,000,000 | $1,844,000,000 | $2,002,000,000 |
| Purchase Of Investment | $-4,072,000,000 | $-736,000,000 | $-2,372,000,000 | $-1,942,000,000 |
| Net Business Purchase And Sale | $-1,070,000,000 | $-4,840,000,000 | $-1,152,000,000 | $-1,797,000,000 |
| Purchase Of Business | $-1,070,000,000 | $-4,840,000,000 | $-1,152,000,000 | $-1,797,000,000 |
| Net PPE Purchase And Sale | $-563,000,000 | $-523,000,000 | $-585,000,000 | - |
| Purchase Of PPE | $-563,000,000 | $-523,000,000 | $-585,000,000 | - |
| Change In Working Capital | $-3,948,000,000 | $-880,000,000 | $-2,303,000,000 | $-1,763,000,000 |
| Change In Other Working Capital | $-2,108,000,000 | $-732,000,000 | $-1,768,000,000 | $-364,000,000 |
| Change In Payables And Accrued Expense | $-126,000,000 | $398,000,000 | $111,000,000 | $-549,000,000 |
| Change In Accrued Expense | $6,000,000 | $108,000,000 | $458,000,000 | $-775,000,000 |
| Change In Payable | $-132,000,000 | $290,000,000 | $-347,000,000 | $226,000,000 |
| Change In Account Payable | $-132,000,000 | $290,000,000 | $-347,000,000 | $226,000,000 |
| Change In Prepaid Assets | $-311,000,000 | $-259,000,000 | $39,000,000 | $-134,000,000 |
| Change In Inventory | $-1,036,000,000 | $-426,000,000 | $-842,000,000 | $-310,000,000 |
| Change In Receivables | $-367,000,000 | $139,000,000 | $157,000,000 | $-406,000,000 |
| Changes In Account Receivables | $-367,000,000 | $139,000,000 | $157,000,000 | $-406,000,000 |
| Other Non Cash Items | $1,504,000,000 | $5,016,000,000 | $1,982,000,000 | $1,724,000,000 |
| Stock Based Compensation | $894,000,000 | $835,000,000 | $766,000,000 | $637,000,000 |
| Asset Impairment Charge | $590,000,000 | $4,180,000,000 | $50,000,000 | $2,700,000,000 |
| Deferred Tax | $160,000,000 | $-1,844,000,000 | $-962,000,000 | $-1,552,000,000 |
| Deferred Income Tax | $160,000,000 | $-1,844,000,000 | $-962,000,000 | $-1,552,000,000 |
| Depreciation Amortization Depletion | $2,760,000,000 | $2,767,000,000 | $2,693,000,000 | $2,103,000,000 |
| Depreciation And Amortization | $2,760,000,000 | $2,767,000,000 | $2,693,000,000 | $2,103,000,000 |
| Amortization Cash Flow | $2,390,000,000 | $2,386,000,000 | $2,339,000,000 | $1,780,000,000 |
| Amortization Of Intangibles | $2,390,000,000 | $2,386,000,000 | $2,339,000,000 | $1,780,000,000 |
| Depreciation | $370,000,000 | $381,000,000 | $354,000,000 | $323,000,000 |
| Gain Loss On Investment Securities | $-451,000,000 | $274,000,000 | $167,000,000 | $657,000,000 |
| Net Income From Continuing Operations | $8,510,000,000 | $480,000,000 | $5,613,000,000 | $4,566,000,000 |
| Change In Tax Payable | - | - | - | $-568,000,000 |
| Change In Income Tax Payable | - | - | - | $-568,000,000 |
Fetched: 2026-05-23